rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ANTX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      AN2 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business and Scientific Highlights
      Nov 9Yahoo FinanceANTX
      AN2 Therapeutics COO Eizen reports $11,925 in stock sale
      Nov 6Investing.comANTX
      AN2 Therapeutics selects oral ENPP1 inhibitor for HPP treatment
      Nov 4Investing.comANTX
      AN2 Therapeutics Advances Pipeline With Development Candidate Nomination for Hypophosphatasia (HPP)

      MENLO PARK, Calif., November 04, 2026--AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical-stage biopharmaceutical company discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the advancement of AN2-504661, a novel boron-based ENPP1 inhibitor, as a development candidate for the treatment of HPP.

      Nov 4Yahoo FinanceANTX
      AN2 Therapeutics Receives FDA Clearance for Phase 2 Epetraborole Study in Polycythemia Vera
      Nov 2Yahoo FinanceANTX
      AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms
      Oct 21Yahoo FinanceANTX
      AN2 Therapeutics to Participate at Upcoming Investor Conferences
      Oct 20Yahoo FinanceANTX
      GSK (LSE:GSK) The Latest Update Raises A Bigger Question
      Sep 30Yahoo FinanceANTXGSK
      AN2 Therapeutics Gets Gates Foundation Funding Extension for Tuberculosis Research

      AN2 Therapeutics (ANTX) has received extended funding from the Gates Foundation for its tuberculosis

      Sep 28Yahoo FinanceANTX
      AN2 Therapeutics: A Failed Drug Could Become A Major Value Driver (NASDAQ:ANTX)
      Sep 22Seeking AlphaANTX
      AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)
      Sep 16Yahoo FinanceANTX
      An2 therapeutics director Robin Readnour sells $6,674 in shares
      Sep 11Investing.comANTX
      An2 therapeutics director Robin Readnour sells $97,322 in shares
      Sep 9Investing.comANTX
      An2 therapeutics director buys $11,601 in common stock
      Sep 2Investing.comANTX
      AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

      MENLO PARK, Calif., August 31, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that four abstracts highlighting clinical and nonclinical data supporting the development of epetraborole, a novel boron-containing oral candidate for the treatment of polycythemia vera (PV), will be presented at the Society of Hematologic Onco

      Aug 31Yahoo FinanceANTX
      AN2 Therapeutics names Cameron Trenor as chief medical officer
      Aug 24Investing.comANTX
      AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer

      MENLO PARK, Calif., August 24, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the appointment of Cameron Trenor, M.D., as Chief Medical Officer.

      Aug 24Yahoo FinanceANTX

      This is the newest page. Registered accounts read further back.